CO2023005600A2 - Derivados de pirazol como inhibidores de la ret-cinasa - Google Patents

Derivados de pirazol como inhibidores de la ret-cinasa

Info

Publication number
CO2023005600A2
CO2023005600A2 CONC2023/0005600A CO2023005600A CO2023005600A2 CO 2023005600 A2 CO2023005600 A2 CO 2023005600A2 CO 2023005600 A CO2023005600 A CO 2023005600A CO 2023005600 A2 CO2023005600 A2 CO 2023005600A2
Authority
CO
Colombia
Prior art keywords
ret
kinase inhibitors
pyrazole derivatives
compounds
formula
Prior art date
Application number
CONC2023/0005600A
Other languages
English (en)
Inventor
Johnathan Alexander Mclean
Manoj Kumar
Erin D Anderson
Steven W Andrews
Kevin R Condroski
Thomas C Irvin
Elizabeth A Mcfaddin
Megan L Mckenney
Michael J Munchhof
Christopher Pierre Albert Jean Boldron
Gabrielle R A/K/A Jody Gabrielle Rustmann Kolakowski Kolakowski
Tiphaine Mouret
Thomas Pierre Dino Pancaldi
Michael Alexander Pilkington-Mikas
Marta Pinto
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CO2023005600A2 publication Critical patent/CO2023005600A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

En la presente descripción se describen compuestos de Fórmula I: o una sal farmacéuticamente aceptable de este, donde las variables son como se definen en la presente descripción. Estos compuestos son útiles en el tratamiento de cánceres asociados a RET. También se describen formulaciones que contienen los compuestos de Fórmula I y métodos para preparar los compuestos de Fórmula I.
CONC2023/0005600A 2020-11-06 2023-05-02 Derivados de pirazol como inhibidores de la ret-cinasa CO2023005600A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063110643P 2020-11-06 2020-11-06
PCT/US2021/058206 WO2022098970A1 (en) 2020-11-06 2021-11-05 Pyrazole derivatives asr et kinase inhibitors

Publications (1)

Publication Number Publication Date
CO2023005600A2 true CO2023005600A2 (es) 2023-05-29

Family

ID=78806726

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0005600A CO2023005600A2 (es) 2020-11-06 2023-05-02 Derivados de pirazol como inhibidores de la ret-cinasa

Country Status (18)

Country Link
US (2) US11697647B2 (es)
EP (1) EP4240738A1 (es)
JP (2) JP7338072B2 (es)
KR (1) KR20230104146A (es)
CN (1) CN116438179A (es)
AR (1) AR124007A1 (es)
AU (1) AU2021376367A1 (es)
CA (1) CA3197032A1 (es)
CL (1) CL2023001277A1 (es)
CO (1) CO2023005600A2 (es)
CR (1) CR20230193A (es)
DO (1) DOP2023000088A (es)
EC (1) ECSP23033180A (es)
IL (1) IL302542A (es)
MX (1) MX2023005289A (es)
PE (1) PE20231984A1 (es)
TW (2) TWI790810B (es)
WO (1) WO2022098970A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20230193A (es) * 2020-11-06 2023-07-03 Lilly Co Eli Derivados de pirazol como inhibidores de la ret-cinasa

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105051027A (zh) * 2013-03-15 2015-11-11 葛兰素史密斯克莱知识产权发展有限公司 作为转染期间重排(ret)激酶抑制剂的吡啶衍生物
WO2017145050A1 (en) 2016-02-23 2017-08-31 Glaxosmithkline Intellectual Property Development Limited Pyridylpyridone derivative useful as a ret kinase inhibitor in the treatment of ibs and cancer
TW201738228A (zh) 2016-03-17 2017-11-01 藍圖醫藥公司 Ｒｅｔ之抑制劑
WO2020035065A1 (zh) 2018-08-17 2020-02-20 南京明德新药研发有限公司 作为ret抑制剂的吡唑衍生物
AR121914A1 (es) * 2020-04-27 2022-07-20 Lilly Co Eli Compuestos útiles para inhibir la quinasa ret
CR20230193A (es) * 2020-11-06 2023-07-03 Lilly Co Eli Derivados de pirazol como inhibidores de la ret-cinasa

Also Published As

Publication number Publication date
JP7338072B2 (ja) 2023-09-04
AU2021376367A1 (en) 2023-05-11
ECSP23033180A (es) 2023-06-30
TW202315623A (zh) 2023-04-16
EP4240738A1 (en) 2023-09-13
AR124007A1 (es) 2023-02-01
TW202233180A (zh) 2022-09-01
CN116438179A (zh) 2023-07-14
JP2023099116A (ja) 2023-07-11
MX2023005289A (es) 2023-07-26
US11697647B2 (en) 2023-07-11
TWI790810B (zh) 2023-01-21
AU2021376367A9 (en) 2023-07-13
CR20230193A (es) 2023-07-03
DOP2023000088A (es) 2023-07-16
IL302542A (en) 2023-07-01
JP2023504303A (ja) 2023-02-02
PE20231984A1 (es) 2023-12-12
US11970485B2 (en) 2024-04-30
WO2022098970A9 (en) 2023-04-27
WO2022098970A1 (en) 2022-05-12
US20220144816A1 (en) 2022-05-12
CA3197032A1 (en) 2022-05-12
CL2023001277A1 (es) 2023-12-01
KR20230104146A (ko) 2023-07-07
US20230265085A1 (en) 2023-08-24

Similar Documents

Publication Publication Date Title
CL2019000368A1 (es) Inhibidores de cdk2/4/6.
CL2020002748A1 (es) Inhibidores de cinasa dependientes de ciclina
ECSP21091615A (es) Derivados de benzisoxazol sulfonamida
CO2022006858A2 (es) Inhibidores de pequeñas moléculas de mutante g12c de kras
CL2017002207A1 (es) Inhibidores del factor beta de crecimiento de transformación (tgf-beta)
UY37900A (es) Nuevos derivados de rapamicina
CL2021000481A1 (es) Inhibidores de sarcómeros cardíacos.
ECSP21034668A (es) Derivados de 2,3-dihidro-1h-pirrolo[3,4-c]piridin-1-ona como inhibidores de hpk1 para el tratamiento de cáncer
DOP2024000039A (es) Derivados de quinolina como inhibidores de la integrina alfa4beta7
DOP2023000088A (es) Derivados de pirazol como inhibidores de la ret-cinasa
ECSP23045506A (es) DERIVADOS DE INDOL ÚTILES EN EL TRATAMIENTO DE AFECCIONES ASOCIADAS CON cGAS
CL2019001023A1 (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia.
CO2020010306A2 (es) Compuestos de sulfonimidoilpurinona 7-sustituida y derivados para el tratamiento y profilaxis de cáncer de hígado.
CO2023001668A2 (es) Derivados de 1h-benzo[d]imidazol como inhibidores de tlr9 para el tratamiento de fibrosis
CL2022002975A1 (es) Compuestos y composiciones para inhibir la actividad de hif2-alfa y sus métodos de uso
ECSP16083017A (es) Derivados de diheterociclo enlazado a cicloalquilo
CO2023012702A2 (es) Derivados de diazepina útiles en el tratamiento de clostridium difficile
CO2021004873A2 (es) Inhibidores de o-glicoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa
PE20211454A1 (es) Derivados de imidazopiridina y su uso como medicamento
AR125479A1 (es) Inhibidores de il4i1 y métodos de uso